Lisata Therapeutics (LSTA) AI Stock Analysis

• Market Cap: $45.52M
• Dividend Yield: N/A
• Average Volume (3M): 34.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: N/A
• EPS Growth: 15.32%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 9,032,291
• 10 Day Avg. Volume: 57,561
• 30 Day Avg. Volume: 34,515
• PEG Ratio: 0.05
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 95.05
• P/FCF Ratio: -1.01
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 173.92
• Enterprise Value/Gross Profit: 190.75
• Enterprise Value/Ebitda: -1.64
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.03
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $5.00 ▲(156.41% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held down primarily by weak financial performance (limited/volatile revenue, continued losses, and ongoing cash burn) despite low leverage. Technicals are supportive with an established uptrend but show overbought risk. Earnings-call commentary adds some support via improving expense discipline and runway into 2027, though the need for additional Phase III funding remains a meaningful overhang; valuation is not especially helpful given negative earnings and no dividend.

Positive Factors

Conservative leverage

Zero or minimal reported debt reduces financial risk and preserves flexibility to pursue partnerships or fund trials without immediate solvency pressure. For a clinical-stage biotech, low leverage lengthens runway options and lowers bankruptcy risk while management seeks non-dilutive or strategic funding.

Strategic partnerships & licensing

Alliances with GATC (AI drug discovery) and a Catalent SMARTag license embed external technical capabilities and commercialization optionality. These partnerships de-risk development, broaden platform applications and can accelerate clinical candidate identification and manufacturing pathways over the medium term.

Expense discipline and runway

Management cut operating and R&D expenses while preserving clinical momentum, extending runway to Q1 2027 on ~$19M cash. Improved cost discipline increases the firm’s ability to reach near-term milestones and negotiate partnerships, giving more time to secure Phase III funding or strategic alternatives.

Negative Factors

Weak cash generation

Persistent negative operating and free cash flow indicate the company cannot self-fund development. Even with modest year-over-year burn improvement, sustained negative cash generation forces reliance on equity, partnerships, or acquisition to finance expensive Phase III trials, raising dilution or execution risk.

Very limited, volatile revenue and losses

Sharp revenue decline and sizable net losses reflect lack of commercial scale and persistent negative margins. Without predictable revenue streams, the company’s ability to fund development internally is constrained, increasing dependency on external capital and reducing visibility on multi-year financial sustainability.

Phase III funding overhang

Management explicitly flagged the need for substantial capital or partnerships for a Phase III trial. This is a structural overhang: securing large-scale trial funding or a partner is uncertain, and failure to do so would delay pivotal development or force dilutive financing, altering long-term strategic options.

Lisata Therapeutics Business Overview & Revenue Model

Company Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

How the Company Makes Money

null

Lisata Therapeutics Financial Statement Overview

Summary

Financial quality is weak: revenue is very limited and volatile (down ~84% in 2025 vs. 2024) with sizable net losses (~-$16.6M in 2025) and persistently negative operating/free cash flow (OCF about -$15.9M in 2025). The main offset is a conservatively levered balance sheet with minimal/no debt, but assets and equity have trended down with ongoing cash burn.

Income Statement

Revenue remains very limited and volatile (down ~84% in 2025 vs. 2024), and the company continues to post sizable losses (2025 net income about -$16.6M). Profitability is weak with deeply negative net margins, reflecting a business still in heavy investment mode. A positive is that losses narrowed versus 2022 levels, but the lack of consistent revenue scale keeps earnings quality and visibility low.

Balance Sheet

The balance sheet is conservatively levered, with minimal to no debt (debt-to-equity near zero across periods, and zero total debt reported in 2025), which reduces financial risk. However, equity and total assets have trended down meaningfully since 2021, consistent with ongoing cash burn, and returns on equity are persistently negative. Overall: strong on leverage, weaker on capital preservation and profitability.

Cash Flow

Cash generation is a key pressure point: operating cash flow is consistently negative (about -$15.9M in 2025 vs. roughly -$19.4M in 2024), and free cash flow is also negative. The burn rate improved modestly year over year, but free cash flow growth is negative in 2025 and cash flows do not cover losses in a way that suggests near-term self-funding. The company likely remains reliant on external capital over time if losses persist.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	170.00K	1.00M	0.00	0.00	0.00
Gross Profit	24.00K	1.00M	0.00	0.00	0.00
EBITDA	-18.06M	-22.23M	-25.52M	-57.53M	-29.00M
Net Income	-16.59M	-19.98M	-20.84M	-54.23M	-27.47M
Balance Sheet
Total Assets	17.74M	35.00M	54.69M	73.03M	97.01M
Cash, Cash Equivalents and Short-Term Investments	15.96M	31.25M	50.53M	69.23M	94.97M
Total Debt	0.00	137.00K	168.00K	485.00K	714.00K
Total Liabilities	3.14M	5.68M	6.80M	6.71M	5.01M
Stockholders Equity	14.86M	29.57M	48.15M	66.58M	92.25M
Cash Flow
Free Cash Flow	-15.98M	-19.36M	-20.03M	-21.45M	-22.30M
Operating Cash Flow	-15.95M	-19.36M	-20.03M	-21.17M	-22.25M
Investing Cash Flow	15.09M	13.23M	10.10M	28.91M	-54.90M
Financing Cash Flow	599.00K	-206.00K	385.00K	-224.00K	85.28M

Lisata Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Positive. The current price of 1.95 is below the 20-day moving average (MA) of 4.55, below the 50-day MA of 3.87, and below the 200-day MA of 2.77, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 72.04 is Negative, neither overbought nor oversold. The STOCH value of 95.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LSTA.

Lisata Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APLM	52 Neutral	$21.53M	-0.14	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LSTA	51 Neutral	$45.52M	-0.97	-84.39%	―	―	15.32%
CTXR	50 Neutral	$19.70M	-0.51	-54.40%	―	―	18.73%
APVO	43 Neutral	$4.67M	-0.19	-389.34%	―	―	99.02%
PCSA	41 Neutral	$7.07M	-0.66	-301.42%	―	―	72.88%

Lisata Therapeutics Corporate Events

Lisata Therapeutics to Be Acquired by Kuva Labs

On March 6, 2026, Lisata Therapeutics agreed to be acquired by privately held Kuva Labs in an all-cash tender offer valuing its common shares at $5.00 each at closing plus one non-tradable contingent value right per share, offering a potential additional $1.00 tied to future regulatory progress for certepetide. The transaction, unanimously recommended by Lisata’s board and expected to close in the second quarter of 2026 subject to a majority tender and other customary conditions, will take Lisata private, delist its stock from Nasdaq and consolidate its oncology-focused pipeline with Kuva’s preclinical NanoMark imaging platform, reshaping incentives for shareholders and aligning future upside with the success of certepetide.

The merger structure includes a second-step merger for untendered shares on identical terms and provides cash and CVR treatment for in-the-money stock options and time-based equity awards, while out-of-the-money options will be canceled without consideration. Termination provisions contemplate a $2 million break fee payable by either side under specified circumstances, and the deal excludes a financing condition, signaling Kuva’s committed funding and adding competitive and execution risk considerations for stakeholders as they evaluate the tender offer.

The most recent analyst rating on (LSTA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Lisata Extends Kuva Labs Acquisition Term Sheet Timeline

Lisata Therapeutics, Inc. and Kuva Labs Inc. had previously entered into a binding term sheet on January 20, 2026, outlining the framework for a potential negotiated acquisition of Lisata by Kuva via a tender offer for all outstanding Lisata common shares, followed by a short-form merger under Section 251(h) of Delaware law. On February 27, 2026, the parties amended the term sheet to extend its expiration to March 7, 2026, signaling continued progress toward a definitive purchase agreement and maintaining transaction optionality for Lisata shareholders while the tender offer has yet to formally commence and remains subject to regulatory filings and customary closing conditions.

The contemplated deal structure could lead to a full change of control of Lisata if sufficient shares are tendered and the merger is completed, potentially reshaping its strategic direction and ownership profile. However, the company highlights significant uncertainties, including the timing and consummation of the tender offer and merger, possible competing bids, and potential business disruption and litigation risks, underscoring that there is no assurance the transaction will close as envisioned and that stakeholders face both opportunity and execution risk as negotiations continue.

The most recent analyst rating on (LSTA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Lisata Therapeutics ends Qilu certepetide collaboration deal

On January 23, 2026, Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. mutually agreed to terminate their exclusive license and collaboration agreement, originally signed in February 2021 and subsequently amended, which had granted Qilu rights to research, develop and commercialize certepetide in Greater China. The termination, effective the same day, eliminates Lisata’s potential to receive up to $200 million in development and commercial milestone payments and 10%–15% royalties on sales in that territory, although both parties remain bound by obligations and certain provisions that accrued or were designated to survive prior to the termination, signaling a strategic shift in Lisata’s regional commercialization plans for certepetide.

The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva

On January 20–21, 2026, Lisata Therapeutics announced it had entered into a binding term sheet with privately held Kuva Labs for a negotiated acquisition via an all‑cash tender offer of $4.00 per share, to be followed by a short‑form merger, with Lisata stockholders also eligible for two non‑tradeable contingent value rights worth up to an additional $2.00 per share upon achieving specified certepetide‑related milestones. The offer, unanimously approved by both companies’ boards and expected to be formalized in a definitive purchase agreement before February 27, 2026, represents roughly an 85% premium to Lisata’s most recent closing price, or about 180% including the CVRs, and is structured with exclusivity, standstill and break‑up fee provisions that protect both parties while allowing Lisata to consider superior competing bids; the deal underscores the strategic value Kuva sees in Lisata’s certepetide‑based oncology platform and could deliver a substantial liquidity event for shareholders if the tender offer and subsequent merger close as planned.

The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.